Randomized Phase II Study Comparing 2 versus 3 Cycles of Neo-adjuvant Chemotherapy (Docetaxel+CDDP+5FU) for Patients with Resectable Advanced Esophageal Cancer
Not Applicable
Recruiting
- Conditions
- Resectable Advanced Esophageal Cancer
- Registration Number
- JPRN-UMIN000015788
- Lead Sponsor
- Department of surgery, Kindai univerisity
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 180
Inclusion Criteria
Not provided
Exclusion Criteria
1)inoperable case due to dysfunction of primary organs (brain, heart, lung, liver, kidney) 2)cases with active double cancer 3)cases with serious drug sensitivity and its history 4)female during pregnancy or lactation 5)inappropriate cases determined by primary doctor 6)cases with mental disorder enough to be unable to understand context of the present study 7)cases who have underwent cisplatin-based chemotherapy 8)cases with positivity of HBs antigen
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 2-year progression-free survival
- Secondary Outcome Measures
Name Time Method